Oxymorphone is a semi-synthetic opioid analgesic indicated for moderate to severe pain. It is approximately 10 times as potent as morphine. Oxymorphone was originally formulated in the 1950s as Numorphan for parenteral administration as the hydrochloride salt, available in 1 mg/mL and 1.5 mg/mL solutions and as a 5-mg suppository. In June 2006, Endo Pharmaceuticals (Chadds Ford, PA) released oxymorphone as Opana for oral use in both immediate-release (5 and 10 mg) and extended-release (5, 10, 20, and 40 mg) tablets of the hydrochloride salt.
Introduction
Oxymorphone is a semi-synthetic opioid analgesic indicated for moderate to severe pain. It is approximately 10 times as potent as morphine. Oxymorphone was originally formulated in the 1950s as Numorphan for parenteral administration as the hydrochloride salt, available in 1 mg/mL and 1.5 mg/mL solutions and as a 5-mg suppository. In June 2006, Endo Pharmaceuticals (Chadds Ford, PA) released oxymorphone as Opana for oral use in both immediate-release (5 and 10 mg) and extended-release (5, 10, 20 , and 40 mg) tablets of the hydrochloride salt.
Oxymorphone, formulated as Opana, has an elimination half-life of 7-11 h, reaches steady-state concentration with multiple dosing after 3 days, and has an oral bioavailabilty of 10%. Peak plasma concentrations for oxymorphone as Opana range from 0.001 to 0.007 mg/L for immediate release doses of 5-20 mg and from 0.0002 to 0.004 mg/L for extended-release doses of 5-40 mg (1, 2) . Oxymorphone is extensively metabolized in the liver, forming two major metabolites, oxymorphone-3-glucuronide and 6-OH-oxymorphone, and resulting in < 1% of the free parent drug being excreted in the urine (1). Oxymorphone's analgesic power is limited only by the user's tolerance to its side effects, the most dangerous being respiratory depression. The ability of oxymorphone to generate feelings of euphoria makes it a target for abuse. It was, however, not widely abused before the advent of Opana because of the non-user-friendly formulation of Numorphan and limited availability. Opana is widely prescribed for chronic pain, and it is responsible for an increase in accidental deaths in the State of North Carolina.
Until recently, oxymorphone was only detectable in our laboratory by a directed gas chromatography-mass spectroscopy (GC-MS) assay for opiates. Unless the history or circumstances surrounding the death suggested oxymorphone was involved, this drug eluded detection. Because of our increased awareness of Opana-related deaths, an oxycodone/oxymorphone enzyme immunoassay (EIA) was introduced in the laboratory to screen for this drug. The existing GC-MS confirmation method was revalidated to lower the linearity range and limit of detection.
To date, only two other incidences of oxymorphone concentrations in postmortem specimens have been reported (3, 4) . The aim of this study was to provide reference ranges for oxymorphone distribution in postmortem fluids and tissue to aid in the interpretation of these specimens in potential overdose cases.
Extraction
Sample preparation. Utilizing 1-mL aliquots of blood/urine and 1-g aliquots of liver homogenate, internal standard was added to each sample. With the exception of the urine samples, acetonitrile (~2.5 mL) was added to each sample to allow for protein precipitation. After vortex mixing and allowing precipitation to occur, the samples were centrifuged at 3000 rpm for 10 min. The supernatants were then transferred to a clean test tube and evaporated under nitrogen to a volume of~1 mL. To all samples, 0.1 M acetate buffer (pH 4.5, 2 mL) and 10% hydroxylamine (0.5 mL) were added to create oxime derivatives of the keto analytes. The sample tubes were capped and placed in a heat block for 1 h at 60°C.
SPE. After cooling, water (2 mL) was added to each sample. The samples were vortex mixed and centrifuged for 10 min at 3000 rpm. The SPE cartridges were conditioned by the sequential addition of methanol (2 mL), water (2 mL), and 0.1 M acetate buffer (pH 4.5, 2 mL). Samples were then introduced onto the cartridges and allowed to flow by gravity. The cartridges were washed with 0.1 M acetic acid (2 mL), water (2 mL), and hexane (2 mL) before drying under a full vacuum for 10 min. Methanol (2 mL) was added to each cartridge before drying under full vacuum for a further 10 min. The target drugs were eluted with a mixture of dichloromethane/isopropanol/ammonium hydroxide (80:18:2, 2 mL) and collected into clean conical tubes. The extracts evaporated to dryness under nitrogen at 40°C.
Derivatization. Each sample was reconstituted with acetonitrile (20 µL) and BSFTA + 1% TMCS (20 µL). The tubes were capped and placed on a heating block at 100°C for 20 min. After cooling to room temperature, the extracts were transferred to autosampler vials ready for GC-MS analysis.
Instrumentation
Initial screening by EIA was performed on a Microgenics MGC 240 analyzer, utilizing a cutoff of 10 ng/mL.
Oxymorphone confirmation by GC-MS was performed on an Agilent 6890 GC equipped with a J&W Scientific (Agilent Technologies, Wilmington, DE) DB-1MS narrow bore capillary column (30 m × 0.25-mm i.d., 0.25-µm film thickness) interfaced with a Hewlett-Packard 5973 mass selective detector. Splitless injections of 1 µL were made with an inlet temperature of 250°C. Helium was the carrier gas at a flow rate of 2.5 mL/min with an initial oven temperature of 160°C. The oven temperature was then ramped at a rate of 35°C/min to 195°C, 5°C/min to 240°C, and 30°C/min to a final temperature of 300°C, holding for 2 min for a total analysis time of 14 min. Electron impact ionization was utilized in the selected ion monitoring mode for the following ions (quantitation ion underlined): m/z 532, 517, and 459 (oxymorphone) and m/z 480 and 465 (oxycodone-d 6 ).
Results
Since 1999, through August 2008, there have been 33 cases involving oxymorphone at the OCME-NC (Table I) present in blood and urine at less than 10% the concentration of oxycodone when oxycodone is ingested (2), cases in which oxymorphone was present at less than 10% of the oxycodone concentration were excluded. were usually > 0.50 mg/L. The distribution of oxymorphone concentrations across the range for each specimen type is shown in Figure 2 . These concentrations largely represent deaths due to oxymorphone toxicity and are not representative of concentrations in which there was another cause of death, such as trauma. There were 28 accidental deaths due to oxymorphone toxicity, alone or in combination with other drugs, three deaths ruled as natural (cases 1, 11, and 16), one homicide (case 30), and one suicide (case 18) with oxymorphone as the causative agent. The assay was linear for oxymorphone from 0.025 to -0.50 mg/L with a least-squares linear regression analysis correlation coefficient (r 2 ) of 0.998 or better. The limits of quantitation and detection were 0.025 mg/L and 0.015 mg/L, respectively with all calibrators within 25% of target. Accuracy and precision studies were performed with a control spiked at 0.075 mg/L. The assay was 97% accurate (n = 15 between run) with a coefficient of variation of 3.8% (n = 5 within run) and 9.6% (n = 15 between run).
Discussion
Prior to 2006 when Opana was released, only two cases from the OCME-NC were reported to contain oxymorphone since 1999. In fact, it was not until 2007 that oxymorphone-related deaths became prevalent in this laboratory. This began with a death that occurred in June 2007 (case 4). Initially, the only history given was a suspected drug related death. After extensive analyses produced no toxicological explanation for the death, the case was certified as "undetermined". Upon subsequent discussion with the medical examiner involved, it was revealed that a 5 mg Opana tablet was found near the body. A directed test for oxymorphone utilizing a GC-MS confirmation assay showed the presence of oxymorphone in the aorta blood of 0.069 mg/L. Since this pivotal case, eight more cases in 2007 were reported and in instances where no toxicological cause of death was found initially, the directed test for oxymorphone was ordered. In January of 2008, the laboratory instituted an oxycodone/oxymorphone EIA test. There have been 21 reported cases in 2008 through August. Cases reported with an undetermined cause of death between June 2006 and the first case known to involve Opana in 2007, were reanalyzed for oxymorphone. No additional oxymorphone-related cases were discovered. The total incidence of undetected oxymorphone-related deaths prior to the release of Opana in June 2006 will remain unknown although they are likely to be few since Numorphan was not widely utilized outside of hospitals.
The demographics for deaths involving oxymorphone are shown in Figure 3 . The most common age range was 30-40 year olds (37%) with deaths occurring predominantly in males (73%). Ninety-four percent of the decedents were Caucasian. The majority of deaths occurred in individuals with a history of drug abuse (Table I) .
Of interest, there were at least three cases where Opana was abused other than being taken orally; intravenous abuse (case 4) and insufflation (cases 6 and 23). With only 10% oral bioavailabilty, this makes administration of Opana via means other than the gastrointestinal tract, extremely dangerous. According to a well-known website where drug abusers record their experiences (7), Opana is most often taken by insufflation and has been described as "worth the money", "the champagne of opioids", "good but horrible", and "near death".
Six cases of accidental oxymorphone toxicity (cases 4, 7, 15, 19, 32, and 33) involved ethanol greater than 20 mg/dL, and one case (case 6) had a history of consumption of ethanol in addition to oxymorphone ingestion although no ethanol was detected in the samples. The package insert for Opana ER contains a black-box warning stating that patients must not consume alcoholic beverages, or prescription or non-prescription medications containing alcohol, while on Opana ER therapy. Co-ingestion of Opana ER with alcohol leads to an increased peak plasma concentration of oxymorphone of up to 270% although the mechanism of the interaction is unknown (1) . Previous research has shown that ethanol may reduce glucuronidation of morphine leading to higher concentrations of free morphine in blood (8) . This phenomenon may also occur with oxymorphone in addition to the additive effects of both substances on central nervous system depression. Co-ingestion of oxycodone and oxymorphone was observed in cases 21 and 26. The relative concentrations of oxymorphone compared to oxycodone in the central blood in these cases is inconsistent with oxymorphone being present as the metabolite of oxycodone alone. The cause of death was ruled as a combined drug toxicity in both cases. A case of suicidal oxymorphone ingestion (case 18) had extremely high concentrations of oxymorphone in all fluids and tissues, as might be expected with deliberate ingestion of a drug with the intention to be lethal. The number and type of oxymorphone pills ingested was unknown. Case 29, however, was ruled an accident and had comparable oxymorphone concentrations to the suicidal overdose case. Case 30 involved a homicide, but oxymorphone was not the primary cause of death. The decedent was likely sedated with large amounts of oxymorphone but actually died of carbon monoxide poisoning.
Cases in which oxymorphone was detected but not considered causal for death were those ruled as natural (cases 1, 11, and 16). Case 1 occurred before the advent of Opana. With the benefit of more data on postmortem oxymorphone concentrations in blood, the concentration of oxymorphone appears to be elevated. Because the source of the fluid obtained was unknown, however, and with the presence of natural disease, the role of oxymorphone in this death is unclear. In case 11, the cause of death was due to ischemic heart disease. An elevated concentration of oxymorphone in the central blood specimen was attributed to diffusion of oxymorphone either from the gastric contents or the trachea as a result of agonal aspiration (9) . The trace amount of oxymorphone in the peripheral sample supports this. The cause of death in case 16 was hypertensive heart disease. The oxymorphone concentrations were the lowest observed of all the cases and were approximately equivalent to concentrations observed in antemortem plasma under therapeutic dosing (1) . The presence of oxymorphone being due to oxycodone consumption in this case was ruled out when no oxycodone was detected in the urine.
In one case of death due to oxymorphone toxicity (case 20), an antemortem blood specimen was collected. The concentration of oxymorphone was less than 0.050 mg/L and limited sample prevented a more precise quantitation.
It is apparent from many of the cases reported (Table I ) that the concentration of oxymorphone detected in blood is site-dependent. This is probably largely due to postmortem redistribution/diffusion. There are some cases where the central and peripheral blood samples were approximately equal or where the peripheral sample was higher in concentration than the central. In most of these instances (cases 18, 26, 29, and 30) the concentrations are higher than average in all matrices. In the event of a rapid death such as from intravenous use of oxymorphone, there may be incomplete distribution of the drug also leading to site differences in oxymorphone concentrations. OCME-NC does not perform full toxicological analyses on deaths other than those suspected to be drug related. This means incidental findings of oxymorphone where the death is due to other means, such as trauma, are not often seen in our laboratory. Consequently, the overlap of therapeutic concentrations with the reported lethal concentrations is unknown. As with all opioids, when determining if a concentration was toxic or lethal all factors must be considered, including tolerance, dose, route of administration, and drug-drug interactions.
Conclusions
Since the advent of Opana in June 2006, OCME-NC has observed an increased incidence of deaths involving oxymorphone. Because most opiate EIA kits have only limited cross-reactivity with oxymorphone, an oxycodone/oxymorphone-specific EIA test was implemented in order to reliably screen for oxymorphone.
Opana is intentionally being abused for its euphoric effects and is often fatal when used inappropriately for pain relief. Oxymorphone was present in postmortem blood specimens at concentrations in the range of 0.011 (a natural death) to 0.82 mg/L (an accidental oxymorphone toxicity) and in liver specimens, from none detected (a natural death) to > 2.0 mg/kg (a homicide).
In North Carolina, oxymorphone deaths are most prevalent in white males between the ages of 20 and 40 years with a history of drug abuse. Anecdotally, oxymorphone is most often abused by snorting the crushed Opana pills (7).
It is evident from most of the cases presented that the concentration of oxymorphone in blood is site-dependent. This can be attributed largely to postmortem redistribution. The mean central/peripheral blood ratio is 1 but the median central/peripheral blood ratio is 1.4. Excluding cases 18, 26, 29, and 30, in which the blood concentrations of oxymorphone are extremely high and/or the peripheral specimen contains more oxymorphone than the central, the mean central/peripheral blood ratio is 1.8.
